Life Sciences

Source: Goldman Sachs Asset Management. As December 31, 2024
We operate a robust, multi-channel sourcing engine that leverages Goldman Sachs’ relationships across academic and medical institutions, corporates, venture capital and private equity firms, and company founders and executives.
We believe that many life sciences companies would benefit from scaling privately, but a funding gap has historically forced these companies to go public too early. By better aligning investment capital with company innovation, we hope to drive better outcomes for companies and, ultimately, patients.
We partner with companies to enhance and accelerate value creation by helping them establish the right business and financial strategies, execute, and achieve strong exits.












Source: Goldman Sachs Asset Management as of February 14, 2025. Investments were selected to highlight the largest investments made as of February 14, 2025. We believe these selected case studies should be considered as a reflection of our investment process, and references to these particular assets/portfolio companies should not be considered a recommendation of any particular security, investment, or portfolio company. Any mention of an investment decision is intended only to illustrate our investment strategy and is not indicative of the performance of our strategy as a whole. It should not be assumed that any investment decisions shown will prove to be profitable or any future investment decisions will be profitable or equal the performance of the investments discussed herein. The holdings and/or allocations shown may not represent all of the strategy’s investments. Please contact your Goldman Sachs Asset Management representative to obtain the holdings presented above as well as each holding’s contribution to performance and a complete list of past recommendations. Please see additional disclosures in the appendix.
Precision Medicine
Precision medicine is the ability to deliver medicines that target a patient’s underlying cause of disease based on their genetics or other unique biological characteristics.
Genetic Medicine
Genetic medicine is the ability to alter a patient’s gene expression to treat disease through the introduction or alteration of genetic material.
Cell Therapy
Cell therapy is the ability to use specific, genetically-engineered cells to combat disease or regenerate tissue.
Artificial Intelligence/Machine Learning
Machine learning is the ability to use advanced computation to understand complex biology and design potential therapeutics.
Immunotherapy
Immunotherapy is the ability to engage and manipulate the immune system as an approach to treating disease.
Synthetic Biology
Synthetic biology is the redesign of living systems for useful purposes, including medicines.
Source: Goldman Sachs Asset Management. As of December 31, 2024. This information discusses general market activity, industry or sector trends, or other broad-based economic, market or political conditions and should not be construed as research or investment advice. This material has been prepared by Goldman Sachs and is not financial research nor a product of Goldman Sachs Global Investment Research (GIR). It was not prepared in compliance with applicable provisions of law designed to promote the independence of financial analysis and is not subject to a prohibition on trading following the distribution of financial research. The views and opinions expressed may differ from those of Goldman Sachs Global Investment Research or other departments or divisions of Goldman Sachs and its affiliates. Investors are urged to consult with their financial advisors before buying or selling any securities. This information may not be current and Goldman Sachs has no obligation to provide any updates or changes.










